Navigation Links
Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Date:6/28/2010

CAMBRIDGE, Mass., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

"For decades, our primary treatment option for patients with type 1 diabetes has been the use of insulin alone to control blood glucose levels, while the underlying autoimmune disease continues to progress," said Dr. Thomas B. Repas, Clinical Assistant Professor, Department of Internal Medicine, University of South Dakota, Sanford School of Medicine, and an investigator in the DEFEND-2 study.  "The future potential of otelixizumab opens up the opportunity for an entirely new treatment approach that can intervene at early onset of type 1 diabetes and potentially break the cycle of the continued progression of this disease that patients manage over their entire lifetime."

DEFEND-2 is a randomized, placebo-controlled confirmatory Phase 3 trial designed to enroll up to 400 patients, age 12 to 45, with newly diagnosed autoimmune type 1 diabetes. DEFEND-2 is being conducted at more than 200 sites in North America and Europe. Building on DEFEND-1, the DEFEND-2 clinical trial similarly evaluates the efficacy and safety of otelixizumab in an additional study population of patients
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... DIEGO , Oct. 1, 2014  ResMed (NYSE: ... sleep and the first company to design complete sleep apnea ... educate women about the importance of a good night,s sleep. ... will challenge the myth that feeling tired is just part ... understand that sleep is a critical pillar of health, essential ...
(Date:10/1/2014)...   Cypher Genomics, Inc., the genome informatics ... Ravenel as chief technology officer. Ravenel has more ... and a proven track record of designing and architecting ... has been recognized as a top designer and architect ... industry-wide for delivering innovative products that operate at scale ...
Breaking Medicine Technology:Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2
... Romark Laboratories, L.C., a,privately-owned biopharmaceutical company, today ... clinical trial to evaluate the safety and,efficacy of ... in,U.S. patients with chronic hepatitis C genotype 1 ... of care therapy (peginterferon and,ribavirin). The company expects ...
... Urologist Presents OrBIT Study Results Comparing Percutaneous, Tibial Nerve ... ... Meeting, MINNEAPOLIS, May 21 Uroplasty, Inc. (Amex:,UPI), ... proprietary products for the treatment of voiding dysfunction,today highlighted ...
Cached Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 2Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 3
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product manufacturer and retailer. ... the global customers in the past few years. Now, ... items. All its online workers are professional and patient; ... The company has recently added a new assortment of ... company’s marketing specialist has announced that all these brand ...
(Date:10/2/2014)... News) -- Children with autism are more sedentary than ... being more active, a small study suggests. Researchers ... some with autism and some without. Children with autism ... activity and 70 more minutes each day sitting than ... scored lower on strength, but had similar body-mass index ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... and the District of Columbia now have a total of ... that has been infecting children since the summer, U.S. ... virus have died in recent weeks, but it,s not clear ... those deaths, officials said. Health officials are also trying ...
(Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
(Date:10/1/2014)... the adage that encourages people to keep their "eyes ... comes to exercise. When walking, staying focused on a ... appear shorter and help people walk there faster, psychology ... to walking while looking around the environment naturally, offers ... , "People are less interested in exercise if physical ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... a recent study in the journal Obesity Research. Body fat ... //tissues are of two types- subcutaneous fat and visceral fat. ... may make the people more at risk to prostate cancer. ... same number of healthy counterparts by assessing their body fat ...
... air pollution due to combustion has been proved to cause ... The research was done by Columbia Center for Children’s Environmental ... Columbia University, US. ,The researchers had observed the ... aromatic hydrocarbons (PAH) that can penetrate placenta to affect the ...
... past have suggested early onset wheezing is associated with ... bronchial hyper-responsiveness. Children with the longest duration of wheezing ... children who develop wheeze later in childhood end up ... early. ,This study involved nearly 1,500 children born ...
... a herb used in traditional Indian medicine to treat ... // in a manner similar to prescription drugs. ... salacia oblonga, which is native to regions of India ... that break down carbohydrates in the body. These enzymes ...
... Pseudomonas aeruginosa is a potentially life-threatening infection for ... doctors often prescribe an inhaled drug called colistin ... drug is controversial because some patients experience chest ... severe coughing and reduced lung function. However a ...
... New research shows children younger than age 1 can learn certain ... // in one context and understand them in another, researchers worked ... ,The parents used 12 board books and a set of 48 ... and chairs in simple games with their children. The games were ...
Cached Medicine News:
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Designed for stab incisions...
Medicine Products: